// App-Quantinova.ai

TPS5100 : TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Emmanuel S. Antonarakis

Principal Investigators

  • Paraskevi Giannakakou

  • Brian J. Kirby

  • Leonardo V. Nicacio

  • Mario A. Eisenberger

  • David M. Nanus

  • Scott T. Tagawa

Medical Centers

  • Weill Cornell Medical College, New York, NY

  • Sanofi-Aventis, Bridgewater, NJ

  • Sibley School of Mechanical and Aerospace Engineering, Cornell University, Ithaca, NY

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Cabazitaxel

  • Docetaxel

  • taxane

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT01718353

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved